News

Filter

Current filters:

Gilead SciencesDiabetes

Drug pricing power led by hepatitis C, diabetes and cancer

Drug pricing power led by hepatitis C, diabetes and cancer

13-06-2014

Hepatitis C, diabetes and cancer are sustaining high pricing power through innovation according to Morningstar's…

AbbVieAntibiotics and Infectious diseasesBiogen IdecCopaxoneDiabetesGenericsGilead SciencesMerck & CoOncologyPharmaceuticalPricingTecfideraTeva Pharmaceutical IndustriesUSA

Gilead's Ranexa reduces angina frequency in patients with type 2 diabetes

11-03-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) has announced data from the Phase IV TERISA (Type 2 Diabetes…

BiotechnologyCardio-vascularDiabetesGilead SciencesPharmaceuticalRanexaResearch

COMPANY SPOTLIGHT

Menarini

Back to top